Contract Number: QLRT – 2000 - 01404
from 1st November 2001 to 31st January 2005

Miltefosine for leishmaniasis: Molecular basis of mechanisms of action, resistance and combination therapy
Acronym: MILTLEISH

Partner 1: Prof Simon Croft, London School of Hygiene & Tropical Medicine, London, UK.
simon.croft@lshtm.ac.uk

Partner 2: Dr Francisco Gamarro
Instituto de Parasitologia y Biomedicina “Lopez-Neyra”, Granada, Spain:
gamarro@ipb.csic.es

Partner 3: Dr Philippe Loiseau
Chimiotherapie Antiparasitaire, UMR 8076 CNRS, Faculty of Pharmacy, University of Paris XI, Chatenay-Malabry, France. philippe.loiseau@cep.u-psud.fr

Partner 4: Dr Luis Rivas
Centro de Investigaciones Biologicas (CSIC), Madrid, Spain,. luis_rivas@cib.csic.es

Partner 5: Dr Oliver Kayser
Freie Universitat Berlin, Institute for Pharmacy, Berlin, Germany
kayser@zedat.fu-berlin.de

Partner 6: Dr Daniel Perrissoud
Zentaris AG, Frankfurt am Main, Germany
daniel.perrissoud@zentaris.de



Project Structure – focus *L. donovani*



3 Workpackages

2 Major Objectives

Project Output



Key Scientific advances

- Mechanism of resistance – a novel aminophospholipid translocase (also expressed in amastigotes)
- Induces apoptosis-like death in promastigotes
- Alteration of fatty acid and sterol metabolism in promastigotes
- SAR studies identified more selective (100x) analogues
- Miltefosine – AL drug interactions – mainly indifferent *in vitro* and *in vivo*
- New HPLC method for detection of miltefosine

Publications

- 13 primary papers
- 4 reviews
- Invited presentations at Keystone and ICAAC meetings

Impact

- Basis for pre-clinical and clinical studies on drug combinations for VL
- Tools (LdMT and LdRos3 molecular markers) for miltefosine resistance (to be validated)
- No further patents taken out on miltefosine analogues